Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | OXTR | P30559 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.43 |
| ▸ | GHSR | Q92847 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4030623 | 0.95 | HSD11B1 (0.52) | HSD11B1CNR1CNR2OXTRLMNA | |
| SCHEMBL5420834 | 0.88 | HSD11B1 (0.50) | HSD11B1CNR1CNR2OXTRLMNA | |
| SCHEMBL24026180 | 0.78 | HSD11B1 (0.60) | HSD11B1CNR1CNR2LMNAMAPK14 | |
| SCHEMBL1572985 | 0.76 | CCNC (0.57) | HSD11B1CHRNA7 | |
| SCHEMBL3455478 | 0.75 | HSD11B1 (0.49) | HSD11B1CNR1CNR2OXTRLMNA | |
| SCHEMBL21851716 | 0.75 | CHRNA3 (0.68) | CHRNA7 | |
| SCHEMBL4028207 | 0.75 | CHRNA3 (0.64) | LMNACHRNA7 | |
| SCHEMBL3455562 | 0.75 | L3MBTL3 (0.71) | OXTRCCR3CHRM2 | |
| SCHEMBL3390463 | 0.75 | CCR3 (0.59) | OXTRCCR3MAPK14CHRM2 | |
| SCHEMBL3388512 | 0.75 | CCR3 (0.59) | OXTRCCR3MAPK14CHRM2GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539764-B1 | ARYL-SUBSTITUTED DIAZABICYCLOALKANES AS NICOTINIC ACETYLCHOLINE AGONISTS. | ASTRAZENECA AB (SE) | 2009-04-29 | — | — | EP | disclosed |
| US-20060052368-A1 | Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | disclosed |
| EP-1539764-A1 | ARYL-SUBSTITUTED DIAZABICYCLOALKANES AS NICOTINIC ACETYLCHOLINE AGONISTS. | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004016616-A1 | ARYL-SUBSTITUTED DIAZABICYCLOALKANES AS NICOTINIC ACETYLCHOLINE AGONISTS. | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052368-A1 | Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists | CHRNA7, CHRNB1, CHRNA1 | HSD11B1 1637/4885CNR1 38/4885CNR2 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.